Conference call - FDA positionThe FDA discussion during the conference call was inadequate - no new insights or progress to report since the April 10 press release. The specific underlying reasons for the FDA rejection, and the Company's plans for a re-submission will only be revealed in August. Surely it cannot be that complicated? Let's hope that management is being forthright.